Celiac Disease - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 72 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Celiac Disease - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Celiac Disease - Pipeline Review, H2 2014', provides an overview of the Celiac Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Celiac Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Celiac Disease and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Celiac Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Celiac Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Celiac Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Celiac Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Celiac Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Celiac Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Celiac Disease Overview 8
Therapeutics Development 9
Pipeline Products for Celiac Disease - Overview 9
Pipeline Products for Celiac Disease - Comparative Analysis 10
Celiac Disease - Therapeutics under Development by Companies 11
Celiac Disease - Therapeutics under Investigation by Universities/Institutes 13
Celiac Disease - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Celiac Disease - Products under Development by Companies 17
Celiac Disease - Products under Investigation by Universities/Institutes 18
Celiac Disease - Companies Involved in Therapeutics Development 19
ActogeniX NV 19
Alba Therapeutics Corporation 20
Alvine Pharmaceuticals, Inc. 21
Avaxia Biologics, Inc. 22
Calypso Biotech SA 23
Dr. Falk Pharma GmbH 24
ImmusanT, Inc. 25
Provid Pharmaceuticals, Inc. 26
Zedira GmbH 27
Celiac Disease - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
AVX-176 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Biologic to Antagonize HLA-DQ2 for Celiac Disease - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Biologics to Inhibit Transglutaminase 2 for Celiac Disease - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CALY-002 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Enzyme for Celiac Disease - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ERW-1041E - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Genetically Engineered Bacteria for Celiac Disease - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
larazotide acetate - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
latiglutenase - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Monoclonal Antibody to Inhibit IL-2 and IL-15 for Oncology and Gastrointestinal Disorders - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Nexvax-2 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Nexvax-3 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Peptide for Celiac Disease - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Synthetic Peptide to Inhibit DQ2/DQ8 for Celiac Disease and Type 1 Diabetes - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ZED-101 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ZED-1098 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ZED-1219 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
ZED-1227 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ZED-754 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Celiac Disease - Recent Pipeline Updates 58
Celiac Disease - Dormant Projects 62
Celiac Disease - Product Development Milestones 63
Featured News & Press Releases 63
Jun 12, 2014: Potential New Treatment May Protect Celiac Patients from Gluten-Induced Injury 63
Feb 11, 2014: Alba Therapeutics Announces Positive Results of Phase IIb Trial in Celiac Disease 63
Oct 29, 2013: Alvine Pharmaceuticals Doses First Patient in Phase 2b Trial for ALV003 in Celiac Disease 64
Aug 06, 2013: ImmusanT Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes 65
Apr 19, 2013: ImmusanT's Epitope-specific Immunotherapy For Celiac Disease Informs Potential Of Vaccines Against Other Autoimmune Diseases 66
Sep 05, 2012: Alvine Pharma's ALV003 Receives Fast Track Designation From FDA For Treatment Of Celiac Disease 66
Sep 04, 2012: ImmusanT Initiates Clinical Trials Of Nexvax2 Therapeutic Vaccine For Celiac Disease 67
May 22, 2012: Alvine Presents Phase IIa Trial Results Of ALV003 In Celiac Disease Patients At 2012 Digestive Diseases Week Meeting 68
May 01, 2012: Alba Gains Exclusive Rights To Patient Reported Outcome Questionnaire For Patients With Celiac Disease 69
Jan 11, 2012: Microtest Laboratories To Manufacture ImmusanT's Nexvax2 Immunotherapeutic Vaccine For Expected Clinical Trial 70
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 72
Disclaimer 72

List of Tables
Number of Products under Development for Celiac Disease, H2 2014 9
Number of Products under Development for Celiac Disease - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Comparative Analysis by Unknown Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Celiac Disease - Pipeline by ActogeniX NV, H2 2014 19
Celiac Disease - Pipeline by Alba Therapeutics Corporation, H2 2014 20
Celiac Disease - Pipeline by Alvine Pharmaceuticals, Inc., H2 2014 21
Celiac Disease - Pipeline by Avaxia Biologics, Inc., H2 2014 22
Celiac Disease - Pipeline by Calypso Biotech SA, H2 2014 23
Celiac Disease - Pipeline by Dr. Falk Pharma GmbH, H2 2014 24
Celiac Disease - Pipeline by ImmusanT, Inc., H2 2014 25
Celiac Disease - Pipeline by Provid Pharmaceuticals, Inc., H2 2014 26
Celiac Disease - Pipeline by Zedira GmbH, H2 2014 27
Assessment by Monotherapy Products, H2 2014 28
Number of Products by Stage and Target, H2 2014 30
Number of Products by Stage and Mechanism of Action, H2 2014 32
Number of Products by Stage and Route of Administration, H2 2014 34
Number of Products by Stage and Molecule Type, H2 2014 36
Celiac Disease Therapeutics - Recent Pipeline Updates, H2 2014 58
Celiac Disease - Dormant Projects, H2 2014 62